Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 7/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28414703 | 0.95 | AR (0.55) | USP30ARDPP7PREPDPP4 | |
| SCHEMBL28210486 | 0.82 | USP30 (0.43) | USP30MBTD1L3MBTL3L3MBTL1MAPT | |
| SCHEMBL6674309 | 0.79 | DPP4 (0.45) | ARDPP7L3MBTL1DPP4DPP8 | |
| SCHEMBL3767117 | 0.76 | KMT2A (0.44) | USP30ARMBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL3767119 | 0.76 | KMT2A (0.44) | USP30ARMBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL28851318 | 0.76 | AR (0.40) | USP30ARDPP7PREPDPP4 | |
| SCHEMBL2926923 | 0.76 | MBTD1 (0.43) | USP30MBTD1L3MBTL3L3MBTL1MAPT | |
| SCHEMBL1773499 | 0.75 | USP30 (0.49) | USP30ARDPP7DPP4DPP8 | |
| SCHEMBL28515773 | 0.75 | DPP4 (0.47) | ARDPP7L3MBTL1DPP4DPP8 | |
| SCHEMBL138440 | 0.72 | LMNA (0.43) | USP30ARMAPTNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113264881-B | Synthetic method of alpha-cyanide | 南昌大学 | 2022-12-02 | — | — | CN | disclosed |
| CN-113264881-A | Synthetic method of alpha-cyanide | 南昌大学 | 2021-08-17 | — | — | CN | disclosed |
| EP-2488028-B1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-104945382-B | Substituted piperidines that increase p53 activity and uses thereof | 默沙东公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2488028-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| CN-102239158-A | Method for preparing a spiroindoline and a precursor thereof | GLAXO GROUP LTD | 2011-11-09 | — | — | CN | disclosed |
| EP-2370423-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Glaxo Group Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010065704-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
| CN-1675209-A | Dihydropyrazolopyridine compounds | MITSUBISHI PHARMA CORP (JP) | 2005-09-28 | — | — | CN | disclosed |
| EP-1174419-B1 | A method for producing an alpha-aminonitrile from a tertiary amine and a cyanide through oxidation with oxygen by using a transition metal catalyst | UNIV OSAKA (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6486340-B2 | Method for producing an α-aminonitrile from a tertiary anime and a cyanide through oxidation with oxygen by using a transition metal catalyst | OSAKA UNIVERSITY (JP) | 2002-11-26 | — | — | US | disclosed |
| US-20020042534-A1 | Method for producing an alpha-aminonitrile from a tertiary anime and a cyanide through oxidation with oxygen by using a transition metal catalyst | OSAKA UNIVERSITY (JP) | 2002-04-11 | — | — | US | disclosed |
| EP-1174419-A1 | A method for producing an alpha-aminonitrile from a tertiary amine and a cyanide through oxidation with oxygen by using a transition metal catalyst | OSAKA UNIVERSITY (JP) | 2002-01-23 | — | — | EP | disclosed |
| US-5756748-A | ALKYLATING 4-CYANO-4-PHENYLPIPERIDINE, PRECIPITATING AS HYDROCHLORIDE SALT, HYDROLYZING TO ACID, REACTING WITH OXALYL CHLORIDE OR THIONYL CHLORIDE AND ETHYLMETHYLAMINE TO FORM AMIDE | ASTRA AB (SE) | 1998-05-26 | — | — | US | disclosed |
| EP-0799203-A1 | NEW PROCESS FOR THE PREPARATION OF SAMERIDINE | Astra Aktiebolag (SE) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019453-A1 | NEW PROCESS FOR THE PREPARATION OF SAMERIDINE | ASTRA AKTIEBOLAG (SE) | 1996-06-27 | — | — | WO | disclosed |
| US-4093620-A | Process for producing 2-cyano N-substituted heterocyclic compounds and products produced thereby | PHILIP MORRIS INCORPORATED (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | TP53, TP53BP1, MDM2 | USP30 1254/4885AR 2820/4885DPP7 425/4885 |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | TP53, MDM2, TP53BP1 | USP30 1122/4885AR 2819/4885DPP7 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.